Armistice reports 3.76M TVTX shares (4.21%)

Accepted by SEC EDGAR 02/17/2026 - 09:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd filed Amendment No. 8 to a Schedule 13G/A reporting beneficial ownership of 3,763,891 shares of Travere Therapeutics, Inc.

The filing states this equals 4.21% of the class and shows shared voting and shared dispositive power over 3,763,891 shares as of 12/31/2025. The filing is a joint reporting statement by Armistice Capital (investment manager to the Master Fund) and Steven Boyd, dated 02/17/2026.

Insights

Institutional Ownership Analyst

Armistice reports a 4.21% stake in Travere with shared voting and disposition rights.

Armistice Capital and Steven Boyd report beneficial ownership of 3,763,891 shares, equal to 4.21% of common stock as of 12/31/2025. The schedule clarifies Armistice acts as investment manager to the Master Fund, which directly holds the shares.

Holder decisions and any future amendments will be disclosed in subsequent filings; timing and intended disposition strategies are not included in the excerpt.

Corporate Governance Specialist

Filing shows joint reporting and shared authority, with standard disclaimers by the Master Fund.

The statement explains Armistice Capital exercises voting and investment power under an Investment Management Agreement and that the Master Fund "disclaims beneficial ownership" due to its contractual restrictions. Shared voting/dispositive power is recorded at 3,763,891 shares.

Look for any later amendments or Form 13D filings if intentions change; the excerpt contains no change-of-control or transaction instructions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Armistice Capital report in Travere Therapeutics (TVTX)?

Armistice Capital reports beneficial ownership of 3,763,891 shares, representing 4.21% of the common stock as of 12/31/2025. The position is reported via a joint Schedule 13G/A amendment dated 02/17/2026.

Who is reported as the beneficial owner alongside Armistice Capital on the 13G/A?

The filing lists Steven Boyd jointly with Armistice Capital, identifying Mr. Boyd as the managing member who may be deemed to beneficially own the shares held by the Master Fund.

Does the filing indicate Armistice has sole voting or dispositive power over the shares?

No. The filing reports 0 shares with sole voting or dispositive power and 3,763,891 shares with shared voting and shared dispositive power, per the ownership table.

What entity actually holds the reported shares according to the filing?

The direct holder is the Armistice Capital Master Fund Ltd., a Cayman Islands fund; Armistice Capital is disclosed as the investment manager exercising voting and investment power under an Investment Management Agreement.

Did the Master Fund claim beneficial ownership of the reported shares?

The Master Fund expressly disclaims beneficial ownership of the securities it directly holds to the extent it cannot vote or dispose of them because of its Investment Management Agreement with Armistice Capital.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

TRAVERE THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

89422G107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 89422G107

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,763,891.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,763,891.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,763,891.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.21 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 89422G107

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,763,891.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,763,891.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,763,891.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.21 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TRAVERE THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 89422G107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,763,891
(b)	Percent of class: 4.21%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,763,891
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,763,891 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	02/17/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	02/17/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd